Mandate

Vinge advises Industrifonden in coNnection with investment in FishBrain

November 21, 2013

Industrifonden has invested MSEK 5 in FishBrain, a company which has developed a mobile solution and a social network for sport fishermen. Sport fishing is the world’s most popular leisure time activity with 100 million sport fishermen worldwide. The capital will be used to implement the business model and to finance the company’s international expansion.

FishBrain’s mobile solution and social network connects sport fishermen, distributors, manufacturers of sport fishing equipment and arrangers of sport fishing trips. It makes it possible for fishing enthusiasts worldwide to share information, tips and compare fish caught and locations.
The company’s vision is to be the leading global social network for sport fishermen and to continue its expansion in the Nordic region, the UK, Russia, China, the US and Japan.

Vinge’s team consisted of responsible partner Johan Larsson, together with partner Jonas Bergström and associate Karl Hahtovirta.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026